guest ::
| Home > Publications database > Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. > print |
| Home > Publications database > Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. > print |
| 001 | 142489 | ||
| 005 | 20240229105148.0 | ||
| 024 | 7 | _ | |a 10.1080/2162402X.2018.1428157 |2 doi |
| 024 | 7 | _ | |a pmid:29872552 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5980408 |2 pmc |
| 024 | 7 | _ | |a 2162-4011 |2 ISSN |
| 024 | 7 | _ | |a 2162-402X |2 ISSN |
| 024 | 7 | _ | |a altmetric:32214387 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-00208 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Michels, Judith |b 0 |
| 245 | _ | _ | |a Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. |
| 260 | _ | _ | |a Abingdon |c 2018 |b Taylor & Franics |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1680684091_11713 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Purpose: Determine the prognostic and predictive significance of tumor associated antigen (TAA)-specific serum antibodies in melanoma patients of a large adjuvant vaccination phase III trial. Patients and methods: Serum IgG antibodies were measured against a panel of 43 antigens by a bead-based multiplex assay in 970 stage II melanoma patients of the EORTC18961 trial, evaluating adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation. Primary end point was relapse-free survival (RFS). Patients' sera at baseline, after 12 and 48 weeks of study treatment and at the last available time point (at recurrence/remission) were evaluated. Results: Prognostic clinical variables are gender, surgical confirmation of lymph node-negative status, Breslow thickness and ulceration of the primary. Prognostic spontaneous antibody responses were associated with a significant dismal (GM2, Rhod_E2, SSX2) or good prognosis (CyclinB1, SCYE1v1) for RFS, distant metastasis-free (DMFS) or overall survival (OS). Predictive spontaneous antibody responses based on significant interaction with treatment were RhodN p = 0.02, Rab38 p = 0.04 for RFS, RhodE2 p = 0.006, Recoverin p = 0.04 for DMFS and RhodE2 p = 0.003; Recoverin p = 0.04, NA17.A p = 0.04, for OS respectively. The subgroups of patients according to antibody responses for RFS were determined for RhodN sero-negative (n = 849, HR = 1.07, p = 0.6); RhodN sero-positive (n = 121,HR = 0.42, p = 0.01) and Rab38 sero-negative (n = 682, HR = 1.12, p = 0.42), Rab38 sero-positive (n = 288, HR = 0.65, p = 0.04) patients respectively. Conclusion: We identified prognostic serum antibody responses against TAA in stage II melanoma patients. A set of antibody responses correlated with a beneficial outcome for GM2 vaccination. |
| 536 | _ | _ | |a 314 - Tumor immunology (POF3-314) |0 G:(DE-HGF)POF3-314 |c POF3-314 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Becker, Natalia |b 1 |
| 700 | 1 | _ | |a Suciu, Stefan |b 2 |
| 700 | 1 | _ | |a Kaiser, Iris |0 P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec |b 3 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 4 |
| 700 | 1 | _ | |a Kosaloglu-Yalcin, Zeynep |b 5 |
| 700 | 1 | _ | |a Agoussi, Sandrine |b 6 |
| 700 | 1 | _ | |a Halama, Niels |0 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601 |b 7 |
| 700 | 1 | _ | |a Pawlita, Michael |0 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da |b 8 |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 9 |
| 700 | 1 | _ | |a Eichmüller, Stefan |0 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |b 10 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 11 |
| 700 | 1 | _ | |a Eggermont, Alexander M M |b 12 |
| 700 | 1 | _ | |a Zörnig, Inka |0 P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3 |b 13 |
| 773 | _ | _ | |a 10.1080/2162402X.2018.1428157 |g Vol. 7, no. 6, p. e1428157 - |0 PERI:(DE-600)2645309-5 |n 6 |p e1428157 - |t OncoImmunology |v 7 |y 2018 |x 2162-402X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:142489 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 13 |6 P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-314 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Tumor immunology |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ONCOIMMUNOLOGY : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ONCOIMMUNOLOGY : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Infektionen und Krebs-Epidemiologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)F022-20160331 |k F022 |l Infektionen und Krebs-Epidemiologie |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)G183-20160331 |k G183 |l Präklinische T-Zellforschung |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)G182-20160331 |k G182 |l GMP Einheit Zelluläre Therapie |x 5 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F022-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G183-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G182-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|